US equities
|
META
$622.61
▼-1.26%
TSLA
$405.90
▲+3.65%
MU
$931.30
▲+3.05%
NVDA
$217.75
▲+0.81%
SPCX
$149.63
▲+1.86%
AMD
$559.70
▲+5.35%
SNDK
$1,296.11
▲+3.23%
AAPL
$345.54
▲+0.47%
META
$622.61
▼-1.26%
TSLA
$405.90
▲+3.65%
MU
$931.30
▲+3.05%
NVDA
$217.75
▲+0.81%
SPCX
$149.63
▲+1.86%
AMD
$559.70
▲+5.35%
SNDK
$1,296.11
▲+3.23%
AAPL
$345.54
▲+0.47%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
3.210
+0.290 (+9.93%)
Delayed Quote
Updated: 2:15 PM EDT, Oct 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
Lexaria Bioscience Featured in Virtual Coverage of Benzinga's Small Cap Conference
↗
December 08, 2021
Lexaria Bioscience (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company leverages its patented technology, DehydraTECH(TM), to improve the delivery of...
Via
Benzinga
35 Stocks Moving In Wednesday's Mid-Day Session
↗
December 08, 2021
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement of a formal process to explore strategic options...
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction
December 08, 2021
Via
CannabisNewsWire
Why Lexaria Shares Are Rising Today
↗
December 08, 2021
Lexaria Bioscience Corp (NASDAQ:LEXX) is trading higher We...
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction
December 08, 2021
Via
Investor Brand Network
Read Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket?
↗
December 08, 2021
Lexaria Bioscience Corp (NASDAQ: LEXX) has issued follow-up results from human clinical study HYPER-H21-2 of DehydraTECH-processed cannabidiol (CBD). The data...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
December 08, 2021
Gainers Lexaria Bioscience (NASDAQ:LEXX) shares increased by 30.28% to $6.41 during Wednesday's pre-market session. The company's market cap stands at $36.7...
Via
Benzinga
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
December 08, 2021
Results suggest broader applications for DehydraTECH-CBD beyond hypertension KELOWNA, BC / ACCESSWIRE / December 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in Virtual Coverage of Benzinga’s Small Cap Conference
December 07, 2021
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference
December 07, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference
December 07, 2021
Via
Investor Brand Network
Lexaria Bioscience Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
↗
December 03, 2021
Lexaria Bioscience Corp. (NASDAQ:
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
December 02, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
December 02, 2021
Via
Investor Brand Network
Lexaria's DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
↗
November 29, 2021
Lexaria Bioscience Corp
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
November 24, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
November 24, 2021
Via
Investor Brand Network
Lexaria Bioscience's DehydraTECH(TM) Drug Delivery Tech Finding Multiple Applications
↗
November 24, 2021
Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursu...
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications
November 24, 2021
Via
Investor Brand Network
Lexaria Bioscience Announces 2022 DehydraTECH(TM) R&D Programs
↗
November 18, 2021
Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions The program builds...
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes
November 18, 2021
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes
November 18, 2021
Via
CannabisNewsWire
Lexaria Bioscience Corp. Embarks on Ambitious Hypertension Clinical Study
↗
November 15, 2021
Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and its most ambitious yet This study builds on the HYPER-H21-1 and HYPER-H21-2 findings,...
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarks on its Most Ambitious Hypertension Clinical Study Yet: HYPER-H21-4
November 12, 2021
Via
Investor Brand Network
Lexaria Expands 2022 R&D Programs to Evaluate Alzheimer's, Diabetes
↗
November 11, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs...
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes
November 10, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes
November 10, 2021
Via
Investor Brand Network
Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
November 10, 2021
KELOWNA, BC / ACCESSWIRE / November 10, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces its plans for...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Death
Intellectual Property
Lexaria Bioscience Corp. Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology's Efficacy in Reducing/Inhibiting Seizure Activity
↗
November 04, 2021
Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD h...
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio
November 03, 2021
Via
Investor Brand Network
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
